多西他赛联合希罗达治疗转移性乳腺癌临床观察

目的:研究多西他赛联合希罗达治疗复发转移性乳腺癌的疗效及不良反应。方法:对28例复发转移性蒽环类耐药乳腺癌患者采用多西他赛联合希罗达治疗。结果:28例患者经过治疗后,完全缓解(CR)3例(10.7%),部分缓解(PR)9例(32.1%),稳定(SD)12例(42.9%),进展(PD)4例(14.3%)。总有效率(CR+PR)为42.9%,疾病控制率(CR+PR+SD)为85.7%。主要不良反应为骨髓抑制,其中Ⅲ～Ⅳ度白细胞减少占3.6%,其次为手足综合征,恶心、呕吐、腹泻多为Ⅰ～Ⅱ级,对症处理均可耐受。结论:多西他赛联合希罗达治疗复发转移性蒽环类耐药的乳腺癌疗效较好。

Objective ：To research the efficacy and toxicity of Docetxel and Xeloda in the treatment of metastatic breast cancer. Methods ：28 patients with metastatic Breast cancer were treated with Docetaxel and Xeloda. Results ： Among these 28 patients, there were 3 complete response （ 10. 7% ） , partial response 9 （ 32. 1%） , stale disease 12 （42. 9% ） ,progressive disease 4（ Id. 3% ）, and clinical benefit response （CR ＋ PR） 12 （42. 9% ） ,the tumor control rate （ CR ＋ PR ＋ SD） was 24（85. 7% ）. The main toxic reactions were myelosuppression, grade - 3 and g adverse events induding leuopenia 3.6%. Most common grade - 1 and 2 adverse event included hand -foot syndrome, nausea and vomiting, diarrbea, and were tolerable. Conclusion： Good clinical efficacy were chieved in the therapy of metastatic breast cancer with docetaxel and xeloda combination regimen and toxic reaction were tolerable.